Isoprinosine

Inosine pranobex, the active ingredient in Isoprinosine, is an immunomodulator presented as an oral formulation for oral use. It is employed to support the immune response in viral infections such as herpes simplex, influenza, and human papillomavirus‑related warts, and in certain immunocompromised conditions.

GNH USA supplies Isoprinosine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. We support regulatory compliance and post‑market surveillance for all customers.

Isoprinosine acts as an immunomodulatory antiviral, targeting viral replication and enhancing host defenses.

- Herpes simplex infections: reduces lesion duration and severity. - Influenza and other acute viral respiratory infections: shortens illness course and alleviates symptoms. - Subacute sclerosing panencephalitis (SSPE): may slow disease progression. - Human papillomavirus (HPV) warts: promotes regression of cutaneous warts. - Immunostimulation in immunocompromised patients: supports immune function during infections.

Inosine pranobex may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild stomach upset that may be transient or persist during therapy. - Headache: mild to moderate pain often relieved with simple analgesics. - Dizziness: occasional light‑headedness, especially when standing quickly.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of hives, swelling, breathing difficulty and possible shock. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: serious skin rash with blistering and mucosal involvement. - Hepatic enzyme elevation or liver injury: abnormal liver function tests that may indicate liver stress.

Before prescribing Inosine pranobex, clinicians should consider several precautionary measures to ensure safe use.

- Pregnancy: safety not established; use only if potential benefit justifies risk. - Breastfeeding: avoid unless benefits outweigh potential infant exposure. - Renal impairment: assess kidney function; dose adjustment may be required. - Hepatic disease: monitor liver enzymes regularly during treatment. - Concomitant immunosuppressants: evaluate risk of reduced efficacy or increased infection. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Inosine pranobex can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Immunosuppressive agents (e.g., cyclosporine, azathioprine): may diminish antiviral benefit. - Live vaccines: increased risk of vaccine‑derived infection. - Anticoagulants (e.g., warfarin): potential for enhanced bleeding tendency.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of allergic reactions. - Corticosteroids: additive immunomodulatory effects may alter response. - Other antiviral agents: possible additive toxicity; monitor clinical status.